Penn Center for Myeloproliferative Neoplasms

James K Mangan

faculty photo

James K Mangan

Assistant Professor of Clinical Medicine
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-102
34th Street and Civic Center Blvd
Philadelphia, PA 19104
Office: 215-615-3138
Fax: 215-615-5887
Education:
BS (Biology-Molecular, Cellular and Development)
Haverford College, 1998.
Ph.D. (Molecular Biology and Genetics)
Temple University, 2005.
MD
Temple University, 2005.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Hogan JJ, Loren AW, Denker MG, Mangan JK: Edema with hypoalbuminemia as a rare manifestation of chronic graft versus host disease after allogeneic hematopoietic cell transplant. Leukemia and Lymphoma 58(8): 2008-2010, August 2017.

Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO: Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark Survey. Cancer 123(3), February 2017.

Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO. : Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark Survey. Cancer Page: epub ahead of print, September 2016.

Yam C, Crisalli L, Luger SM, Loren AW, Hexner EO, Frey NV, Mangan JK, Gao A, Stadtmauer EA, Porter DL, Reshef R. : Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. American Journal of Hematology 91(9): 883-887, September 2016.

Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci, K, Luger SM, Mangan JK, Grupp SA, Maude SL, Ericson S, Levine BL, Lacey SF, Melehorst JJ, June CH, Porter DL: Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia. American Society of Clinical Oncology Annual Meeting(166823), June 2016.

Mangan JK, Chmieliauskaite M, Stoopler ET. : An intraoral mass associated with myelodysplastic syndrome. JAMA Oncology 2(5): 679-680, May 2016.

Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, Levine BL, June CH, Emerson SG, Porter DL.: Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American Journal of Hematology 91(5): 453-460, May 2016.

Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO: Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark Survey. BMC Cancer 16(167), February 2016.

Ganetsky A, Crisalli LM, Huffman AP, Acosta EP, Mangan JK, Luger SM, Loren AW, Hexner EO, Frey NV, Stadtmauer EA, Hoxie JA, Vonderheide RH, Porter DL, Reshef R. : Maraviroc concentrations are highly predictive of acute graft-versus-host-disease in reduced-intensity allogeneic stem cell transplantation. European Hematology Association Annual Meeting(331), 2016.

Canaani J, Frey NV, Gill S, Luskin MR, Hexner EO, Loren AW, Luger SM, Mangan J, Porter DL, Perl AE. : Use of FLT3 inhibitors to bridge relapsed/refractory AML patients to an allogeneic stem cell transplant. American Society of Bone Marrow Transplanation/Center for International Bone Marrow Transplant Research Tandem Meetings(273), 2016.

back to top
Last updated: 10/12/2017
The Trustees of the University of Pennsylvania
 

The Penn Difference

  • Individualized Treatment Plan
  • Expert Treatment Team Knowledgeable in Myeloproliferative Disorders
  • State-of-the-Art Personalized Diagnostic Testing
  • Access to Newest Therapies Through Clinical Trials
  • Comprehensive Bone Marrow Transplantation Service
  • Integrated Care by a Multidisciplinary Treatment Team

Make an Appointment

New Patients:
Abramson Cancer Center
Perelman Center for Advanced Medicine
2nd Floor, West Pavilion
Philadelphia, PA 19104
Phone: 215-615-5858 option 2
Fax: 215-615-5889

Current Patients:
Contact your doctor directly

For General Inquiries:
Call the Myeloproliferative Neoplasms Program at  215-614-1847


Donate


Search